Sofinnova and Imperial's Mission Therapeutics raises £60m

The round also saw participation from existing investors Imperial Innovations Group, Sofinnova, SR One, Roche Venture Fund and Pfizer Venture Investments.

Imperial committed £11.3m to the round, to be allocated in multiple tranches, with the first £3.9m tranche having already been provided. Imperial's shareholding in Mission following the investment round increased to 21.6%, having invested £5.8m in the company before this round.

Previous funding
Mission's latest funding round brings its total venture capital backing to £86m, having received a £6m injection from Imperial, SR One and Sofinnova in August 2011, followed by a £20m round in November 2013 when Pfizer joined the investor group.

Company
Founded in 2011 and headquartered in Cambridge, Mission is a biotechnology company focused on developing treatments that target debequinating enzymes to treat cancer and neurodebilitating diseases.

People
Imperial Innovations – Rob Woodman (director).
Mission Therapeutics – Anker Lundemose (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Healthcare
• UK / Ireland
• Venture
• United Kingdom
• Sofinnova